ATP5IF1

ATP5IF1 (ATPIF1/IF1) is a mitochondrial regulatory protein whose core activity is inhibition of the reverse, ATP-hydrolyzing mode of the FoF1-ATP synthase, which positions it as a master controller of mitochondrial membrane potential (ΔΨ) and downstream metabolic state (PMID:24685140, PMID:24005319). By blocking ATPase activity, ATPIF1 governs whether ΔΨ is preserved during electron transport chain dysfunction or collapsed during uncoupling: its loss protects cells from complex III blockade and is required for viability of ρ° cells lacking mtDNA, whereas its presence drives ΔΨ collapse that recruits PARK2 and activates PINK1–PARK2 mitophagy (PMID:24685140, PMID:24005319). This control of mitochondrial pH and redox potential also sets the catalytic efficiency of ferrochelatase, linking ATPIF1 to haem biosynthesis (PMID:23135403). In disease-relevant settings, ATPIF1 upregulation in hypertrophied hearts promotes non-productive ATP synthase tetramers that stall electron flow, generate ROS, stabilize HIF1α, and switch metabolism toward glycolysis; cardiac-specific deletion prevents this remodeling (PMID:35575090). Across immune lineages, ATPIF1 tunes the balance between oxidative phosphorylation and glycolysis to shape cell function, including CD8+ T cell proliferation and effector output (PMID:36016697) and neutrophil bactericidal capacity (PMID:37558010). Beyond these themes, ATPIF1 has been linked to additional metabolic and inflammatory phenotypes in endothelial, macrophage, and erythroid contexts, but their mechanisms are less fully resolved in the available corpus.

1. 2012 High

   Established that ATPIF1 is not merely an ATP synthase brake but a metabolic input to haem synthesis, by showing it sets ferrochelatase catalytic efficiency through control of mitochondrial pH and redox state.

   Evidence Zebrafish genetic screen with Fech construct complementation, pharmacological pH/redox modulation, and cross-species haematopoietic models

   PMID:23135403

   Open questions at the time

   • Direct physical interaction between ATPIF1 and ferrochelatase not demonstrated
   • Quantitative link between ΔΨ/pH and Fech turnover not resolved structurally
2. 2013 High

   Defined ATPIF1 as a required driver of mitophagy, showing that its blockade of ATP synthase reverse activity enables ΔΨ collapse needed for PINK1–PARK2 activation.

   Evidence Genome-wide RNAi screen plus ATPIF1 restoration in Rho0 cells with ΔΨ and PARK2 translocation readouts

   PMID:24005319

   Open questions at the time

   • Does not establish whether ATPIF1 acts directly at the PINK1 sensing step or only indirectly via ΔΨ
   • Physiological triggers engaging this pathway in vivo not defined
3. 2014 High

   Clarified the directionality of ATPIF1 function by showing its loss preserves ΔΨ during ETC dysfunction and is essential for ρ° cell survival, confirming inhibition of reverse ATP hydrolysis as the central activity.

   Evidence Genome-wide haploid genetic screen with ATPIF1 knockout cell lines, antimycin treatment, and primary hepatocyte validation

   PMID:24685140

   Open questions at the time

   • Conditions favoring ATPIF1 engagement versus disengagement not fully mapped
   • Regulation of ATPIF1 activity (pH, oligomerization) not addressed here
4. 2019 Low

   Linked ATPIF1 to hemoglobin synthesis via an NF-κB/Alas2 transcriptional route, extending its erythroid role beyond ferrochelatase.

   Evidence siRNA knockdown in hypoxic K562 cells with qRT-PCR and hemoglobin measurement

   PMID:31894674

   Open questions at the time

   • Single siRNA experiment in one cell line without rescue
   • Mechanistic connection between ATPIF1 and NF-κB not established
5. 2021 Medium

   Showed ATPIF1 can preserve mitochondrial integrity and ATP in CCM3-deficient endothelial cells, suppressing mitophagy and rescuing adhesion/migration defects.

   Evidence CCM3 knockdown/KO endothelial progenitor cells with ATPIF1 overexpression and ΔΨ/mitophagy readouts

   PMID:33422124

   Open questions at the time

   • Whether effect is direct or secondary to bioenergetic rescue unclear
   • Single-lab, single-context observation
6. 2022 High

   Provided a structural-mechanistic basis for ATPIF1-driven metabolic switching in disease, showing upregulation promotes non-productive ATP synthase tetramers that stall electron flow and drive ROS–HIF1α glycolytic reprogramming in hypertrophied hearts.

   Evidence Chemical cross-linking mass spectrometry, gain/loss-of-function cell models, and cardiac-specific knockout in pressure overload and MI models

   PMID:35575090

   Open questions at the time

   • Tetramer architecture not resolved at high resolution
   • Whether tetramerization mechanism generalizes beyond cardiac stress unknown
7. 2022 Medium

   Demonstrated ATPIF1 controls CD8+ T cell fitness by maintaining OXPHOS, where its loss drives glycolytic shift and exhaustion and its overexpression enhances effector and memory phenotypes.

   Evidence ATPIF1-KO mice, tumor models, scRNA-seq, Seahorse profiling, and CAR-T overexpression

   PMID:36016697

   Open questions at the time

   • Direct molecular link between ΔΨ control and exhaustion programs not defined
   • Single-lab metabolic-phenotype correlation
8. 2023 Medium

   Extended the immunometabolic theme to innate immunity, showing ATPIF1 inactivation in neutrophils enhances glycolysis-driven ROS/lactate and bactericidal activity.

   Evidence ATPIF1-/- mice, E. coli peritonitis model, Seahorse, and NAC/2-DG pharmacological rescue

   PMID:37558010

   Open questions at the time

   • Cell-intrinsic versus systemic contributions not fully separated
   • Single-lab study
9. 2023 Low

   Associated ATPIF1 with ischemia-reperfusion astrocyte injury through an NF-κB-linked apoptotic program.

   Evidence siRNA knockdown in OGD/R rat astrocytes with apoptosis, ROS, ΔΨ and NF-κB protein readouts

   PMID:36881363

   Open questions at the time

   • Single knockdown without rescue or direct binding data
   • Causal position of ATPIF1 in NF-κB signaling not established
10. 2024 Low

    Provided in vivo evidence that ATPIF1 affects ATP synthase hydrolysis in human Sertoli cells, linking it to mitochondrial dysfunction in azoospermia.

    Evidence siRNA knockdown in primary human Sertoli cells with ATP hydrolysis, ΔΨ, and oxygen consumption assays

    PMID:37903059

    Open questions at the time

    • Single knockdown experiment in one cell type
    • No mechanistic follow-up linking to azoospermia pathology
11. 2024 Medium

    Implicated ATPIF1 in peripheral nerve repair through macrophage-mediated immune responses via CCR2/CCL2 signaling.

    Evidence ATPIF1-KO mice, nerve injury model, RNA-seq, and cell-type-specific flow cytometry

    PMID:39713198

    Open questions at the time

    • How mitochondrial ATPIF1 function couples to CCR2/CCL2 axis unresolved
    • Single-lab finding
12. 2025 Medium

    Showed ATPIF1 is required for terminal erythroid differentiation through OXPHOS/TCA support, with splenic extramedullary compensation upon its loss.

    Evidence ATPIF1-KO mice with integrated RNA-seq, metabolomics, erythroid flow cytometry, and heme quantification

    PMID:41181713

    Open questions at the time

    • Relationship to earlier ferrochelatase/Alas2 haem mechanisms not integrated
    • Single-lab study
13. 2026 Medium

    Identified an ATPIF1-mTOR axis governing radiation-induced M1 macrophage polarization and inflammation.

    Evidence ATPIF1 knockdown in BMDMs/RAW264.7 with radiation, RNA-seq, metabolomics, proline rescue, and rat radiation colitis model

    PMID:41741899

    Open questions at the time

    • Mechanism linking ATPIF1 to mTOR phosphorylation undefined
    • Single-lab study
14. 2026 Medium

    Showed ATPIF1 knockdown in CAR-T cells raises ΔΨ and triggers mPTP opening and mtDNA leakage that activates STING to enhance antitumor responses.

    Evidence ATPIF1 gain/loss in Her2-CAR-T cells, in vitro/in vivo tumor models, and STING inhibitor H151 epistasis

    PMID:41846913

    Open questions at the time

    • Apparent contrast with earlier T cell findings (loss impairs CD8+ function) not reconciled
    • Single-lab study

• How ATPIF1's single biochemical activity—inhibiting ATP synthase reverse mode—produces divergent, sometimes opposing outcomes across cell types (protective versus deleterious; effector-promoting versus exhaustion-promoting) remains unresolved.
• No unifying model reconciling context-dependent ATPIF1 outcomes
• Structural determinants of tetramer formation versus dimer inhibition not defined
• Regulation of ATPIF1 expression/activity across tissues incompletely mapped